Advances in metabolomics as the biomarkers for diagnosis and treatment of lung cancer
Lung cancer is characterized by high mortality,poor prognosis and low 5-year survival rate.At present,the com-prehensive treatment based on chemotherapy is the main treatment for non-small cell lung cancer(NSCLC).According to the stage and the type of lung cancer,patients received comprehensive treatment including surgery,radiotherapy,chemotherapy and targeted therapy.However,the not significance of early symptom,the huge difference of individuals,the resistance of radio-therapy and chemotherapy limited the diagnosis and treatment,which caused harmful effects to patients.Metabolomics plays an increasingly important role in exploring tumor biomarkers,evaluating overall metabolic changes,and studying pathogenesis.This paper mainly reviewed the research progress of biomarkers for the prognosis effect evaluation of lung cancer treatment based on metabolomics technology,so as to provide an important theoretical basis for the individualized precision treatment of lung cancer and help clinical patients to maximize the treatment benefits.
NETL
